StreetInsider.com News Articles

Form 8-K bioAffinity Technologies For: Jun 02

Tue, 02 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26588145.html

Form 8-K bioAffinity Technologies For: Jun 02

Tue, 02 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26588145.html

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

Tue, 02 Jun 2026 08:00:00 -0400

Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices

CyPath® Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced the Society for Advanced Bronchoscopy (SAB) will host a webinar on CyPath® Lung’s expanding role in pulmonary,

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

Tue, 02 Jun 2026 08:00:00 -0400

Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices

CyPath® Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

Tue, 02 Jun 2026 08:00:00 -0400

Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices

CyPath® Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

Tue, 02 Jun 2026 08:00:00 -0400

Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices

CyPath® Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

Tue, 02 Jun 2026 08:00:00 -0400

Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices

CyPath® Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

Tue, 02 Jun 2026 08:00:00 -0400

Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices

CyPath® Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence

Form 8-K bioAffinity Technologies For: May 27

Wed, 27 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26554102.html

Form 8-K bioAffinity Technologies For: May 27

Wed, 27 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26554102.html

bioAffinity Technologies receives Mexico patent allowance for lung cancer test

Wed, 27 May 2026 08:01:19 -0400

bioAffinity Technologies Inc. (NASDAQ: BIAF) announced it received notification of patent allowance from the Mexican Institute of Industrial Property for methods of predicting lung cancer likelihood using flow cytometry.

The patent will protect the use of specific antibodies and the porphyrin TCPP to label cell populations in sputum, along with flow cytometry techniques to determine the presence of lung cancer cells in sputum samples. This patent supports the company's CyPath Lung diagnostic test.

CyPath Lung is a noninvasive test that uses flow cytometry and artificial intelligence with at-home sample collection to assess indeterminate pulmonary nodules in high-risk patients. The test incorporates a

bioAffinity Technologies receives Mexico patent allowance for lung cancer test

Wed, 27 May 2026 08:01:19 -0400

bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology

Wed, 27 May 2026 08:00:00 -0400